<DOC>
	<DOC>NCT00677833</DOC>
	<brief_summary>The primary objective is to confirm the hypothesis that azithromycin used in combination with chloroquine is non-inferior to artemether- Lumefantrine for the treatment of symptomatic, uncomplicated malaria due to P. falciparum in children in African countries.</brief_summary>
	<brief_title>Azithromycin Plus Chloroquine Versus Artemether-Lumefantrine For The Treatment Of Uncomplicated P. Falciparum Malaria In Children In Africa</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria, Falciparum</mesh_term>
	<mesh_term>Lumefantrine</mesh_term>
	<mesh_term>Artemether</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Artemether-lumefantrine combination</mesh_term>
	<mesh_term>Chloroquine</mesh_term>
	<mesh_term>Chloroquine diphosphate</mesh_term>
	<criteria>Girls and boys ≥5 years to ≤12 years (Cohort 1); and ≥6 to ≤59 months of age (Cohort 2) with uncomplicated, symptomatic malaria as indicated by the presence of the following: Blood smears positive for monoinfection with P. falciparum and asexual parasitemia between 1000 100,000 parasites/µL; Documented fever (38.0°C/100.4°F rectal or tympanic; 37.2°C/99.0°F axillary or 37.5°C/99.5°F oral) or history of fever (as reported by the legally acceptable representative) within the prior 24 hours; Appropriate for outpatient treatment; Blood glucose ≥60 mg/dL; Hemoglobin ≥6 g/dl or hematocrit ≥18% without signs of anemiainduced Congestive Heart Failure (CHF); Negative urine pregnancy test for females ≥10 years of age (and of child bearing potential) Peripheral blood smear positive for mixed infection with multiple Plasmodium spp. Severe or complicated malaria including subjects with any of the following: Impaired consciousness (eg, obtundation, unarousable coma), seizures or abnormal neurologic exam suggestive of severe or complicated malaria; Known hemoglobinuria; Jaundice; Respiratory distress; Persistent vomiting; Gross hematuria, as reported by the subject's legally acceptable representative; Recent history of convulsions; Inability to drink or breastfeed; Unable to sit or stand as appropriate for age; Known pregnancy or breastfeeding or positive urine pregnancy test (females ≥10 years of age and of child bearing potential); History of allergy to or hypersensitivity to azithromycin, any macrolide, chloroquine, artemether, any artemisinin derivative, lumefantrine; Any contraindication to any study drug including AZ, CQ and AL; History of treatment with any antimalarial drug (such as halofantrine, chloroquine, quinine, mefloquine, Malarone, SP, artemisinin compounds) or antibacterial with known antimalarial activity (macrolides, doxycycline, clindamycin) within 2 weeks prior to enrollment of a subject (and/or of the mother of a subject who is being breastfed) into the study; Known or suspected cardiovascular, hepatic or renal abnormality that in the opinion of the investigator would place the subject at increased risk to participate in the study.</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>P. Falciparum Malaria</keyword>
	<keyword>drug treatment</keyword>
	<keyword>clinical trial</keyword>
</DOC>